App-Based study aims to predict COPD attacks before they happen
NCT ID NCT04955080
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study followed 216 people with COPD and other health conditions for up to 38 months. Participants used a mobile app to log daily symptoms and other health data. The goal was to find patterns that could predict when a person might have a flare-up or get worse, so doctors can step in earlier.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
216 people
The number who actually took part.
- Started
-
Jan 2022
- Finished
-
Sep 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
We aim to enroll 710 patients with both COPD and complex chronic conditions over 28 months (July 2021 until October 2023). Patients will be followed-up for a 38-month period (July 2021 until August 2024). These patients will be recruited from one of the three pilot sites (n=263 from Medisch Spectrum Twente, Netherlands); n=263 from Policlinico Universitario Fondazione Agostino Gemelli, Italy; n=184 from Tartu Ülikooli Kliinikum, Estonia.
- Ages
-
40 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Clinical diagnosis of COPD according to the GOLD criteria \[5\] (FEV1 \< 80% of the predicted value and FEV1/FVC \< 0.70); * Patients can be included both at stable state and during exacerbation/hospitalization; * At least one comorbidity: diabetes mellitus (glucocorticoid-induced, or stable type 1 or 2), chronic heart failure (clinical diagnosis according to the ESC guidelines), ischaemic heart disease (history of myocardial infarction, angina pectoris), active symptoms of anxiety and/or depression (≥11 Hospital Anxiety and Depression Scale , and/or anxiety or depression symptoms being treated at the time of inclusion); * Under treatment at one of the pilot sites (MST, TUK, GEM); * \>40 years of age; * Smoker or ex-smoker; * Able to understand, read and write the language spoken in the country of the pilot site. * Accessibility to internet; * Written informed consent from the subject prior to participation. Furthermore, 25% of the patients should also have ≥ 2 exacerbations, defined as respiratory problems that required a course of oral corticosteroids / antibiotics in the two years preceding study entry; and/or ≥ 1 hospitalisation for respiratory problems in the two years preceding study entry; and/or modified MRC (mMRC) score of 3 or 4 (COPD patients with these scores have a higher chance of exacerbating). Exclusion Criteria: * Serious other diseases with a low survival rate; * Presence of any other active lung disease (e.g., sarcoidosis); * Severe psychiatric illness, diagnosed by anamnesis; * Maintenance therapy with antibiotics * Patients with cognitive impairment (Mini Mental State Examination (MMSE) \< 24)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Comorbidities and coexisting conditions are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Medisch Spectrum Twente
Enschede, Netherlands
More trials for these conditions
Other studies related to the condition(s) this trial covers.